Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERITA PALG-CLL5
2019-004613-14Phase 2Active
- Sponsor
- Polish Adult Leukemia Group
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of venetoclax and rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Polish Adult Leukemia Group. Primary endpoint: CR/CRi with undetectable bone marrow MRD at end of treatment. Started Sep 2021; status: active.
02
Drugs
venetoclaxrituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2019-004613-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004613-14.